Search 

Invicro was founded with a mission of improving the role and function of imaging in translational drug discovery and development.  To this effort we offer a suite of services and software with applications ranging from tissue to human, from target identification to Phase IV trials across the entire electromagnetic spectrum of imaging techniques.

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.

We are building the most detailed, dynamic, in-silico model of bacterial cell envelope biogenesis, ever assembled. The model is being utilised as a platform to discover and develop an internal pipeline of new antibacterial drugs.

OxStem is a drug discovery company, spun-out from the University of Oxford, with the unique vision of developing in-situ cell programming therapies to treat what are typically (but certainly not exclusively) age-related conditions, such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world), Diabetes and Oncology. 

The idea is straightforward - to use the Stem Cell and Medicinal Chemistry expertise within Chemistry and its associated partners at Oxford to identify new classes of drugs that can re-program or stimulate existing endogenous cells - awakening previously defunct or dormant cellular processes.